Infection Risk in Patients on Multiple Sclerosis Therapeutics

Abstract

The interface of multiple sclerosis (MS) and infection occurs on several levels. First, infectious disease has been postulated as a potential trigger, if not cause, of MS. Second, exacerbation of MS has been well-documented as a consequence of infection, and, lastly, infectious diseases have been recognized as a complication of the therapies currently employed in the treatment of MS. MS is a disease in which immune dysregulation is a key component. Examination of central nervous system (CNS) tissue of people affected by MS demonstrates immune cell infiltration, activation and inflammation. Therapies that alter the immune response have demonstrated efficacy in reducing relapse rates and evidence of brain inflammation on magnetic resonance imaging (MRI). Despite the altered immune response in MS, there is a lack of evidence that these patients are at increased risk of infectious disease in the absence of treatment or debility. Links between infections and disease-modifying therapies (DMTs) used in MS will be discussed in this review, as well as estimates of occurrence and ways to potentially minimize these risks. We address infection in MS in a comprehensive fashion, including (1) the impact of infections on relapse rates in patients with MS; (2) a review of available infection data from pivotal trials and postmarketing studies for the approved and experimental DMTs, including frequency, types and severity of infections; and (3) relevant risk minimization strategies, particularly as they pertain to progressive multifocal leukoencephalopathy (PML).

Infections and the relationship to treatment in neuromuscular autoimmunity

“…Previous studies have shown an association between infection in inflammatory myopathy and exposure to IVIg and azathioprine, as well as an association between infection in myasthenia gravis and mycophenolate mofetil and azathioprine treatments . Studies in multiple sclerosis patients treated with long‐term corticosteroids have shown increased rates of viral, bacterial, fungal, and parasitic infections …”

Drug‐induced progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review

“…Fingolimod has been suggested to have neuroprotective properties because it is able to enter the CNS, and bind to neurons and glia expressing sphingosine 1‐phosphate receptors. Although circulating lymphocytes are decreased, immune function remains largely unaffected . Previous findings suggested that fingolimod is selective for lymphocyte sequestration targeting naïve T cells and central memory T cells, while allowing a subset of effective memory cells to maintain normal function …”

Does Every Patient Require an Intrathecal Baclofen Trial Before Pump Placement?

“…The patient's previous history of spinal headache might place him at a greater risk for developing a second spinal headache [10]. There is also some evidence to suggest that patients with MS who on taking disease‐modifying therapy are at greater risk for infectious complications [11]. An added difficulty in this is patient is his anticoagulation status.…”